10-K Decoder · All companies

Prelude Therapeutics Incorporated

PRLD · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$12.1M$7.00M+73.4%
Operating income−$105M−$140M+25.2%
Net income−$99.5M−$127M+21.8%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 16, 2026

$Q3 2026Year earlierChange
Revenue$5.60M$6.50M−13.8%
Operating income−$14.3M−$20.4M+29.9%
Net income−$12.5M−$19.7M+36.5%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Prelude Therapeutics's revenue in FY2025?
$12.1M in FY2025 (Fiscal year ended Dec 31, 2025), +73.4% vs $7.00M a year earlier, per its 10-K filed Mar 2026.
Was Prelude Therapeutics profitable in FY2025?
No: net income was −$99.5M and operating income −$105M in FY2025.
What was Prelude Therapeutics's revenue in Q3 2026?
$5.60M (−13.8% vs a year earlier), per its Form 10-Q filed Nov 16, 2026.